Caris Life Sciences Inc (CAI) is now in the Undervalued zone, suggesting that its current forward PS ratio of 8.41 is considered Undervalued compared with the five-year average of 271.48. The fair price of Caris Life Sciences Inc (CAI) is between 478.29 to 489.32 according to relative valuation method. Compared to the current price of 19.39 USD , Caris Life Sciences Inc By Undervalued By 95.95%.

Relative Value

Fair Zone

478.29-489.32

Current Price：19.39

95.95%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Caris Life Sciences Inc (CAI) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Caris Life Sciences Inc (CAI) has a current Price-to-Book (P/B) ratio of 15.91. Compared to its 3-year average P/B ratio of 16.23, the current P/B ratio is approximately -1.96% higher. Relative to its 5-year average P/B ratio of 16.23, the current P/B ratio is about -1.96% higher. Caris Life Sciences Inc (CAI) has a Forward Free Cash Flow (FCF) yield of approximately -0.18%. Compared to its 3-year average FCF yield of -1.04%, the current FCF yield is approximately -82.23% lower. Relative to its 5-year average FCF yield of -1.04%, the current FCF yield is about -82.23% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CAI competitors is 880.13, providing a benchmark for relative valuation. Caris Life Sciences Inc Corp (CAI.O) exhibits a P/S ratio of 8.41, which is -99.04% above the industry average. Given its robust revenue growth of 125.44%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CAI increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CAI in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CAI currently overvalued or undervalued?

Caris Life Sciences Inc (CAI) is now in the Undervalued zone, suggesting that its current forward PS ratio of 8.41 is considered Undervalued compared with the five-year average of 271.48. The fair price of Caris Life Sciences Inc (CAI) is between 478.29 to 489.32 according to relative valuation method. Compared to the current price of 19.39 USD, Caris Life Sciences Inc is Undervalued By 95.95%.

What is Caris Life Sciences Inc (CAI) fair value?

CAI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Caris Life Sciences Inc (CAI) is between 478.29 to 489.32 according to relative valuation method.

How does CAI's valuation metrics compare to the industry average?

The average P/S ratio for CAI's competitors is 880.13, providing a benchmark for relative valuation. Caris Life Sciences Inc Corp (CAI) exhibits a P/S ratio of 8.41, which is -99.04% above the industry average. Given its robust revenue growth of 125.44%, this premium appears sustainable.

What is the current P/B ratio for Caris Life Sciences Inc (CAI) as of Mar 02 2026?

As of Mar 02 2026, Caris Life Sciences Inc (CAI) has a P/B ratio of 15.91. This indicates that the market values CAI at 15.91 times its book value.

What is the current FCF Yield for Caris Life Sciences Inc (CAI) as of Mar 02 2026?

As of Mar 02 2026, Caris Life Sciences Inc (CAI) has a FCF Yield of -0.18%. This means that for every dollar of Caris Life Sciences Inc's market capitalization, the company generates -0.18 cents in free cash flow.

What is the current Forward P/E ratio for Caris Life Sciences Inc (CAI) as of Mar 02 2026?

As of Mar 02 2026, Caris Life Sciences Inc (CAI) has a Forward P/E ratio of 634.82. This means the market is willing to pay $634.82 for every dollar of Caris Life Sciences Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Caris Life Sciences Inc (CAI) as of Mar 02 2026?

As of Mar 02 2026, Caris Life Sciences Inc (CAI) has a Forward P/S ratio of 8.41. This means the market is valuing CAI at $8.41 for every dollar of expected revenue over the next 12 months.

CAI Valuation